查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
未分化多形性肉瘤治疗的全球市场-2022-2029
市场调查报告书
商品编码
1129248

未分化多形性肉瘤治疗的全球市场-2022-2029

Global Undifferentiated Pleomorphic Sarcoma Therapeutics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

越来越多的针对未分化多形性肉瘤的临床试验预计将推动市场增长。

2020 年 7 月 21 日，Tracon Pharmaceuticals Inc. 宣布宣布接受 1 或 2 线化疗后出现进展的局部晚期、不可切除或转移性未分化多形性肉瘤 (UPS)/肌纤维肉瘤 (MFS)，这是一个关键队列评估 emvaforimab 单独或与 ipilimumab 联合用于患有以下疾病的患者的研究这项研究处于第 2 阶段。此外，美国国家癌症研究所 (NCI) 和 M.D. 安德森癌症中心在一项 2 期试验中，研究了已转移到身体其他部位、局部扩散到附近组织和淋巴结的间变性多形性肉瘤。 sintilimab 用于復发性肉瘤、復发（recurrence）和无法手术切除（不可切除）的患者。 Sintilimab 是一种用于免疫疗法的单克隆抗体，有望帮助人体免疫系统对抗疾病并防止肿瘤细胞生长或扩散。因此，从上述陈述来看，预计市场将在预测期内受到驱动。

限制

药物副作用、缺乏疾病意识、有限的医疗机构要求以及政府对药物批准的严格规定是在预测期内阻碍市场的因素。

行业分析

未分化多形性肉瘤治疗市场基于供应链分析、报销方案、定价分析和管道分析等各种行业因素对市场进行了深入分析。

COVID-19 影响分析

COVID-19 大流行正在影响癌症治疗的方方面面。结果，出现了治疗延误和失访的情况。在受大流行影响地区的研究表明，未分化多形性肉瘤的手术减少了。由于在诊断和手术过程中缺乏对患者的考虑，辅助治疗被推迟。这对侵袭性恶性肿瘤的预后产生不利影响，导致肿瘤晚期和预后不良。

此外，实验室已关闭，临床试验推迟。相比之下，虚拟癌症多学科团队会议技术讨论了个人治疗计划和后勤支持。放疗被考虑用于高危、快速生长的肿瘤患者，大分割有望缩短治疗时间。它还有助于更好地分配资源和缩短治疗疗程。此外，大流行将破坏供应炼和流程。许多公司将转移到其他地区以确保产品可用性并保护其供应链。因此，从上面这句话来看，市场受到了影响，预计随着经济活动的恢復，市场将迅速获得牵引力。

全球未分化多形性肉瘤治疗市场报告将提供对大约 45 多个市场数据表、40 多个数字和 180 页的访问。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因子
    • 驱动程序
      • 预计针对未分化多形性肉瘤的临床试验的增加将推动市场增长。
    • 限制因素
      • 预计药物副作用会阻碍市场增长。
    • 机会
    • 影响分析

第五章行业分析

  • 供应链分析
  • 定价分析
  • 未满足的需求分析
  • 管道分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章诊断领域

  • 核磁共振
  • CT 扫描
  • 活检
  • 健康检查
  • 其他

第 8 章按治疗类型

  • 放射治疗
    • 外照射
    • 术中放疗 (IORT)
    • 其他
  • 化疗
  • 靶向药物治疗
  • 免疫疗法
  • 其他

Chapter 9. 按销售额划分的药品销售额

  • 医院药房
  • 零售药房
  • 在线药店
  • 医院
  • 诊断中心
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准
  • 值得关注的重点公司列表

第 12 章公司简介

  • Pfizer Inc.
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Eisai Inc.
  • AdvaCare Pharma
  • Teva Pharmaceuticals USA, Inc.
  • Bristol-Myers Squibb Company
  • Hikma Pharmaceuticals PLC
  • PV Pharma

第 13 章全球未分化多形性肉瘤治疗市场-DataM

简介目录
Product Code: DMPH5807

Market Overview

The Undifferentiated Pleomorphic Sarcoma Therapeutics Market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Soft tissue cancers include malignant fibrous histiocytoma, often undifferentiated pleomorphic sarcoma. It's rare cancer that frequently metastasizes to other body regions and returns after treatment. Surgery to remove the cancer cells is typically the first step in treating undifferentiated pleomorphic sarcoma. The use of medications (systemic therapies), such as chemotherapy, targeted therapy, and immunotherapy, is another possibility (most of the drugs are in clinical trials).

Market Dynamics

Increasing clinical trials for undifferentiated pleomorphic sarcoma is expected to drive market growth.

On July 21, 2020, Tracon Pharmaceuticals Inc. conducted a pivotal cohort study evaluating the use of envafolimab alone or in combination with ipilimumab for the treatment of patients with locally advanced, unresectable, or metastatic undifferentiated pleomorphic sarcoma (UPS)/myxofibrosarcoma (MFS) who have progressed on one or two lines of chemotherapy. The research is in Phase 2. Moreover, In a phase II trial, the National Cancer Institute (NCI) and M.D. Anderson Cancer Center examined the effects of sintilimab in treating patients with undifferentiated pleomorphic sarcoma that has metastasized to other parts of the body, spread locally to nearby tissue or lymph nodes, returned (recurrent), or cannot be surgically removed (unresectable). Sintilimab, a monoclonal antibody used in immunotherapy, may aid the body's immune system combat the disease and prevent tumor cells from proliferating and spreading. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

Side effects of the drugs, lack of awareness about the disorder, limited availability of required healthcare facilities and strict government restrictions on drug approval are some factors the market is expected to get hampered in the forecast period.

Industry Analysis

The undifferentiated pleomorphic sarcoma therapeutics market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, reimbursement scenario, pricing analysis, pipeline analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has affected every aspect of cancer care. As a result, there is a delay in treatment or loss of follow-up. Studies from pandemic-affected areas show diminution in undifferentiated pleomorphic sarcoma surgeries. There was a lack of patient care in diagnostic and surgical procedures and a delay in adjuvant therapy. This adversely affects the prognosis of aggressive malignancies and has resulted in upstaging of the tumour and poor prognosis.

Moreover, research laboratories have been shut down, resulting in delays in clinical trials. In contrast, virtual multidisciplinary cancer team meeting technology discussed individual treatment plans and logistics. Patients with high-risk rapidly proliferating tumors were considered for radiotherapy, and shortening treatment duration by hypofractionation has shown promising results. They also help in better allocation of resources and shorten the treatment course. Additionally, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of economic activities.

Segment Analysis

Radiation therapy segment is expected to hold the largest market share in undifferentiated pleomorphic sarcoma therapeutics market

The radiation therapy segment is expected to dominate in 2021. The segment is benefited because, in the multimodal treatment of soft tissue sarcomas, radiotherapy (RT) is becoming more important. Intensity-modulated, image-guided, and stereotactic radiation are a few technological advancements that have greatly boosted radiotherapy's potential during the past 20 years and improved patient care. They have permitted either dose escalation (with improved efficacy) or toxicity reduction (with the consequent improved functional outcome). Moreover, healthcare providers usually recommend radiation therapy. This powerful combination allows the best chance of preventing the sarcoma from returning to the same area. For instance, external beam radiation is a type of radiation that comes from a machine that moves around you as you lie on a table. The device targets specific areas of the body with radiation. A sarcoma may be shrunk with radiation before surgery to facilitate removal. It can also be used to eliminate cancer cells following surgery. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global undifferentiated pleomorphic sarcoma therapeutics market

In 2021, North America accounted for the highest revenue share. The rising geriatric population, increasing clinical trials, advancement in the diagnosis of sarcoma, and adoption of new imaging guidelines in the region are some factors the market is expected to boost in the forecast period. For instance, according to the Population Reference Bureau, the number of Americans 65 and older will nearly double from 52 million in 2018 to 95 million by 2060, increasing their percentage of the overall population from 16 percent to 23 percent. There is a diversity gap across generations despite the older adult population being more diverse. The racial/ethnic makeup of the population under 18 is changing more quickly than the group over 65.

Moreover, the following imaging suggestions are part of the clinical practice guidelines provided by the National Comprehensive Cancer Network (NCCN) for STS of the extremities, superficial trunk, head, and neck. All lesions with a decent cancer risk should have sufficient primary tumor imaging. Imaging examinations should include cross-sectional magnetic resonance imaging (MRI) with and without contrast to understand better the size and proximity of nearby visceral tissues and neurovascular landmarks. There may be a need for additional computed tomography (CT) scanning with contrast. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the undifferentiated pleomorphic sarcoma therapeutics market are Pfizer Inc., Eisai Inc., AdvaCare Pharma, Teva Pharmaceuticals USA, Inc., Bristol-Myers Squibb Company, Hikma Pharmaceuticals PLC, PV Pharma.

Pfizer Inc.:

Overview:

Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. It has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.

Product Portfolio:

DOXORUBICIN HYDROCHLORIDE: Doxorubicin (DOX) is often first-line treatment of undifferentiated/unclassified soft tissue sarcoma (USTS).

The global undifferentiated pleomorphic sarcoma therapeutics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing clinical trials for undifferentiated pleomorphic sarcoma is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects of the drugs are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs
  • 5.4. Pipeline Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Diagnosis

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 7.1.2. Market Attractiveness Index, By Diagnosis Segment
  • 7.2. MRI*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. CT scan
  • 7.4. Biopsy
  • 7.5. Physical exam
  • 7.6. Others

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 8.2. Radiation therapy*
    • 8.2.1. External beam radiation
    • 8.2.2. Intraoperative radiation therapy (IORT)
    • 8.2.3. Others
    • 8.2.4. Introduction
    • 8.2.5. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Chemotherapy
  • 8.4. Targeted drug therapy
  • 8.5. Immunotherapy
  • 8.6. Others

9. By Treatment Sales

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 9.1.2. Market Attractiveness Index, By Treatment Sales Segment
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies
  • 9.5. Hospitals
  • 9.6. Diagnostic Centers
  • 9.7. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Pfizer Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Eisai Inc.
  • 12.3. AdvaCare Pharma
  • 12.4. Teva Pharmaceuticals USA, Inc.
  • 12.5. Bristol-Myers Squibb Company
  • 12.6. Hikma Pharmaceuticals PLC
  • 12.7. PV Pharma

LIST NOT EXHAUSTIVE

13. Global Undifferentiated Pleomorphic Sarcoma Therapeutics Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us